Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Clovis Oncology Is Poised to Plunge

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Clovis Oncology (Nasdaq: CLVS  ) has received a distressing two-star ranking.

With that in mind, let's take a closer look at Clovis and see what CAPS investors are saying about the stock right now.

Clovis facts

Headquarters (founded)

Boulder, Colo. (2009)

Market Cap

$399.4 million



Trailing-12-Month EBITDA

($62.6 million)


CEO Patrick Mahaffy (since 2009)
CFO Erle Mast (since 2009)

Trailing-12-Month Return on Equity



$162.5 million / $0


Immunomedics (Nasdaq: IMMU  )
Lorus Therapeutics
Threshold Pharmaceuticals (Nasdaq: THLD  )

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 23% of the 22 members who have rated Clovis believe the stock will underperform the S&P 500 going forward.

Just yesterday, one of those Fools, All-Star zzlangerhans, tapped the stock's recent run as particularly unsustainable:

[$400M] isn't an outrageous market cap for a company with [$163M] in cash and two early stage oncology candidates. The thing is, Clovis had the same valuation in August when topline results of their pivotal trial of their lead oncology candidate were still pending. Even though the share price ran up ahead of the crash when the trial failed and development of the lead candidate was terminated, it doesn't make sense for the stock to be running up again so quickly. I think the [S]treet is still showing overconfidence in this management team.

If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2138359, ~/Articles/ArticleHandler.aspx, 10/23/2016 6:17:36 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
CLVS $34.24 Down -0.23 -0.67%
Clovis Oncology CAPS Rating: ***
IMMU $2.24 Down -0.05 -2.18%
Immunomedics CAPS Rating: *****
THLD $0.43 Down -0.01 -1.32%
Threshold Pharmace… CAPS Rating: ***